6698.0000 -39.00 (-0.58%)
NSE May 27, 2025 15:31 PM
Volume: 294.3K
 

KRChoksey
DIVISLAB revenue beat our estimates (+3.9%) due to strong growth in Custom Synthesis segment. EBITDA beat our estimates due to better-than-expected gross profit and lower than expected employee expenses. Adj. PAT was beat due to lower-than-expected effective tax rate.
Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.
More from Divi's Laboratories Ltd.
Recommended